AIM
EGRX

Aigen Investment Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Aigen Investment Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-14,996
Closed -$637K – 1147
2020
Q3 		$637K Buy
+14,996
New +$656K 0.08% 357
2020
Q1 		– Sell
-91
Closed -$5K – 1630
2019
Q4 		$5K Buy
+91
New +$5.43K ﹤0.01% 1014

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Aigen Investment Management's EGRX Position: Q4 2020 in Review

Aigen Investment Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2020, closing a stake of 14,996 shares — an estimated $637K sold.

Aigen Investment Management first reported a position in EGRX in Q4 2019 and held it in 2 quarters. The position peaked at $637K in Q3 2020. 166 funds tracked by Wall St. Rank hold EGRX as of Q4 2020.

  • Aigen Investment Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Aigen Investment Management sold 14,996 Eagle Pharmaceuticals, Inc. shares in Q4 2020, an estimated $637K.
  • Aigen Investment Management first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2019 and held it in 2 quarters.
  • Aigen Investment Management's Eagle Pharmaceuticals, Inc. position peaked at $637K in Q3 2020.
  • 166 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2020.

Based on Aigen Investment Management's 13F filing for Q4 2020, filed 12 Feb 2021.